Ad5-D24-GMCSF

AXP000066.1 · Oncolytic virus

Platform
adenovirus (Ad5, Delta-24, GM-CSF-armed)
Originator
University of Helsinki (Akseli Hemminki)

Names

NameTypeSource
Ad5-D24-GMCSFpreferred name, codecurator, paper

Virus

Role
Oncolytic
Family
Adenoviridae
Virus
human adenovirus 5 (NCBI Taxonomy 28285)
Strain
Ad5
Replication
conditionally replicating
Modifications
24-bp E1A CR2 deletion (Delta-24)
Transgenes
CSF2
Route
intratumoral, intraperitoneal, intrapleural, intravenous
Source
evidence

Approvals

No regulatory approval recorded.

Clinical trials (0)

No trial in the latest ClinicalTrials.gov snapshot names this program.

Recent changes

No changes recorded in its trials yet.

Clinical papers

No confirmed clinical papers yet.

Other papers

Preclinical studies, reviews and other papers that name it.

PubMedTitleJournalYearLinked by
PMID 20484030Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patients.Cancer research2010name in abstract: Ad5-D24-GMCSF

Notes

Given to patients in the Finnish Advanced Therapy Access Program (ATAP, 2007-2012), an individualised-treatment programme rather than a registered trial. Serotype 5 fibre version of the virus that became ONCOS-102 (Ad5/3).

How to cite

Ad5-D24-GMCSF (AXP000066.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000066.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.